Asset profile
Alimatravir
Small molecule
Evidence outlook · registrational
HIV: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2027-07-22.
NCT06045507: The study randomized 352 participants to three MK-8527 dose groups or matched placebo and used double blinding, but Alimatravir was not studied and was not the comparator. Its primary endpoints were safety outcomes rather than efficacy, and the registry provides counts without statistical comparisons, so whether the primary comparisons were met cannot be determined.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 11 direct rivals (same mechanism and indication), 0 same-class, 49 same-indication; 21 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Alimatravir: this drug | Phase 3 | Small molecule | HIV reverse transcriptase | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase | ||
| Etravirine (Intelence) | Approved | Small molecule | HIV reverse transcriptase | ||
| Rilpivirine (Edurant) | Approved | Small molecule | HIV reverse transcriptase | ||
| Tenofovir Alafenamide / Emtricitabine (Descovy) | Approved | Small molecule | HIV reverse transcriptase | ||
| Azvudine (FNC) | Phase 3 | Small molecule | HIV reverse transcriptase | ||
| Dapivirine (Dapivirine Vaginal Ring) | Phase 3 | Small molecule | HIV reverse transcriptase | ||
| Ulonivirine | Phase 2/3 | Small molecule | HIV reverse transcriptase | ||
| CL-197 | Phase 2 | Small molecule | HIV reverse transcriptase | ||
| Ainuovirine | Phase 1 | Small molecule | HIV reverse transcriptase | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2027 (4)
January 2027 (1)
What to watch
July 2027 (1)
What to watch
October 2027 (1)
December 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.